Phase 3 N=288 A Study of LY2216684 in Participants With Major Depression Disorder
Major Depressive Disorder
Primary: Number of Participants With Clinically Significant Events — 0; 1; 0; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=75 Recovery of Diaphragmatic Function After Neuromuscular Blockade and Sugammadex
Diaphragmatic Dysfunction · Muscle Weakness · Muscle Fatigue
Primary: Electric Activity of the Diaphragm (Microvolts) — 3.7; 4.5; 3.2; 2.9 microvolt
Phase 3 N=1,046 Cancer Venous Thromboembolism (VTE)
Venous Thromboembolism (VTE) · Deep Vein Thrombosis (DVT) · Pulmonary Embolism (PE)
Primary: Number of Participants With Adjudicated Recurrent Venous Thromboembolism (VTE) or Major Bleeding Event — 67; 71 Participants — p=0.0056
Phase 3 N=875 A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer
HER2 Positive Early or Locally Advanced Breast Cancer
Primary: The Pathologic Complete Response (pCR) Rate of the Primary Breast Tumour — 42.0; 51.7 percentage of responders
Phase 3 N=91 Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
Anaplastic Medulloblastoma · Medulloblastoma · Supratentorial Embryonal Tumor, Not Otherwise Specified
Primary: Number of Patients Who Have Either a Complete Response (CR) Rate or No Complete Response Rate — 13; 15; 16; 15 Participants — p=0.35
Phase 3 N=420 A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in HbA1c (Glycosylated Haemoglobin) — 8.20; 8.36; -1.94; -1.68 Percentage of glycosylated haemoglobin
Phase 3 N=1,902 Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)
Asthma
Primary: Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: Intent-to-Treat (ITT) Population — 0.871; 0.456; 0.970; 0.524 Exacerbation per…
Phase 3 N=210 Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma
Asthma
Primary: Percentage Reduction From Baseline in Oral Corticosteroids (OCS) Dose at Week 24 While Maintaining Asthma Control — 41.85; 70.09 Percentage reduction from baseline — p=<…
Phase 3 N=769 Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)
HIV-1
Primary: Percentage of Participants Achieving Plasma HIV-1 RNA <50 Copies/mL at Week 48 — 83.8; 79.9 Percentage of participants
Phase 3 N=61 Understanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly (URGE)
Urge Urinary Incontinence
Primary: Percentage With Treatment Success — 74.1; 75.0 percentage of participants — p=1.0
Phase 3 N=457 A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia
Schizophrenia
Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 — -17.9; -17.3; -13.1 units on a scale — p=0.050
Phase 3 N=444 A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
Diabetes
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) at Week 52 — -1.35; -0.98 % HbA1c — p=<0.001
Phase 3 N=16,395 HIV Vaccine Trial in Thai Adults
HIV Infection
Primary: Kaplan-Meier Estimate of HIV-1 Infection Rate in Intent to Treat Population — 0.15; 0.38; 0.41; 0.64 Percetage of subjects
Phase 3 N=460 Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia
Schizophrenia
Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 (LOCF) — -6.1; -4.3; -2.5; -7.1 units on a scale — p=0.149
Phase 3 N=284 Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia
Schizophrenia
Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at LOCF Endpoint — -28.4 units on a scale